Search results for "Axel"
showing 10 items of 257 documents
German Adjuvant Intergroup Node Positive (GAIN) study: A phase III trial to compare IDD-ETC versus EC-TX in patients with node-positive primary breas…
2014
1009 Background: Intense dose-dense (idd) epirubicin (E), paclitaxel (T), cyclophosphamide (C) (idd-ETC) resulted in a superior disease-free (DFS) and overall survival (OS) compared to conventional...
Final results of OV16, a phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel (CP) versus CP in first-line chemoth…
2013
5502 Background: Topotecan was evaluated in a novel combination regimen in comparison to standard therapy in front-line EOC. Methods: Women with newly diagnosed advanced EOC stages IIB-IV, ECOG performance status (PS) 0-1, age < 75, were randomized to either Arm 1: cycles 1 - 4: cisplatin 50 mg/m2 d1 plus topotecan 0.75 mg/m2 d1-5 IV; cycles 5 - 8: paclitaxel 175 mg/m2over 3 hrs d1 followed by carboplatin AUC5 day 1 or Arm 2: paclitaxel plus carboplatin as in Arm 1 for 8 cycles. The primary endpoint was progression free survival (PFS) and secondary endpoints included objective response, overall survival (OS), adverse event (AE) and Quality of Life (QoL). The sample size required 800 pts…
Target Therapy in Platinum-Refractory/Resistant Ovarian Cancer: From Preclinical Findings to Current Clinical Practice
2013
Epithelial ovarian cancer (EOC) is the sixth most common malignancy in women. Ovarian tumors consist of several clinical and pathological entities that share an anatomic site. The gold standard treatment, both in front-line and in adjuvant setting, is represented by carboplatin/paclitaxel combination. Conversely, the second-line treatment is not well defined. The response to platinum is the major prognostic factor for survival. In this review we discuss the current views on platinum-refractory/resistant patient treatment only, which includes patients progressing or relapsing within 6 months from the last platinum-based course. Concerning this subgroup, the activity of several conventional d…
Brief an Garlieb H. Merkel
1797
Ms. 930a, Nr. 6, Bl. 15r-16r Bruiningk, Karl Axel Christer Freiherr von. Brief an Garlieb H. Merkel, Halle, den 3. Oct[ober] 1797 Autora rokraksts / Autograph, vācu val. / Deutsch, [3] lpp. / S. Attēlu numuri / Bildnummern: 930a-006-1 – 930a-006-2-3 Der spätere Verfechter für die Bauernbefreiung in Livland und Reformer landwirtschaftlicher Methoden Karl Alexander Christer von Bruiningk drückt im Alter von 16 Jahren Merkel gegenüber seinen Dank und seine Bewunderung aus. Zum Zeitpunkt des Schreibens befindet sich der Autor im „Königlichen Pädagogium“ in Halle, also einem Teil der Franckeschen Stiftungen. Diese Muster-Bildungsanstalt war einer der Stationen von Bruiningks Bildungsweg, die meh…
Demokraattisen kokeilullisuuden puolesta, kapitalismia vastaan
2019
Kirja-arvostelu teoksesta Axel Honneth, Sosialismin idea (Die Idee des Sozialismus, 2015). Suom. Arto Kuusterä & Jussi Palmusaari. Gaudeamus, Helsinki 2018. 224 s. nonPeerReviewed
Hindrances to recognition in Finnish music schools
2021
This article examines recognition relations between students and teachers in Finnish music schools. The research is based on written texts by music school students. The texts are analysed for difficulties in recognition relations, namely, hindrances to recognition in music schools. In the texts, some of the respondents describe situations that can be analysed as hindrances to recognition. The author analyses four different types of recognition-related problems in the data, the main issue being a tension between caring for people (respecting them) and promoting musical values (emphasising esteem). In addition to discerning problems, the article attempts to alleviate this tension. This might…
Social Invisibility and Emotional Blindness
2020
The unsettling, humiliating, and often threatening experience of feeling oneself ‘invisible’ before the gazes of other people in one’s social world has obvious potential as a theme for collaborative efforts between social theorists and phenomenologists. This chapter proposes one way of approaching such an engagement, drawing in particular upon three authors who offer detailed analyses of social visibility and its potential pathologies: Axel Honneth, Frantz Fanon, and Edmund Husserl. The specific phenomenon is first be located by way of Honneth’s treatment of social invisibility as frequented by behaviour that expresses an attitude of nonrecognition towards other persons immediately present.…
EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab pl…
2019
10–20% of patients with gastric cancer (GC) have HER2+ tumors. Addition of trastuzumab (T) to cisplatin/fluoropyrimidine-based chemotherapy (CT) improved survival in metastatic, HER2+ GC. When pertuzumab (P) was added to neoadjuvant T and CT, a significant increase in histopathological complete response rate was observed in HER2+ breast cancer. This study aims to investigate the added benefit of using both HER2 targeting drugs (T alone or the combination of T + P), in combination with perioperative CT for localized HER2+ GC. This is a prospective, randomized, open-label, phase II trial. HER2 status from patients with resectable GC (UICC TNM7 tumor stage Ib-III) will be centrally determined.…
Nintedanib plus docetaxel after progression on immune checkpoint inhibitor therapy: insights from VARGADO, a prospective study in patients with lung …
2019
Aim: To assess outcomes in patients with advanced adenocarcinoma non-small-cell lung cancer who received nintedanib plus docetaxel after progression on prior chemotherapy followed by immune checkpoint inhibitor (ICI) therapy. Patients & methods: VARGADO is a prospective, noninterventional study. We describe initial data from a cohort of 22 patients who received nintedanib plus docetaxel after chemotherapy and ICI therapy. Results: Median progression-free survival with nintedanib plus docetaxel was 5.5 months (95% CI: 1.9–8.7 months). The objective response rate was 7/12 (58%) and the disease control rate was 10/12 (83%). Data for overall survival rate 12 months after the start of treat…
The Clinical Efficacy of Enzalutamide in Metastatic Prostate Cancer: Prospective Single-center Study
2017
Background/Aim: To evaluate the effectiveness of enzalutamide in Italian patients with hormone-refractory metastatic castration-resistant prostate cancer, progressing after chemotherapy with docetaxel plus prednisone. Patients and Methods: A total of 60 patients were enrolled. Reduction in serum prostate-specific antigen (PSA) was assessed as the primary endpoint, while reduction in pain, safety, progression-free survival and overall survival represented secondary endpoints. Results: Enzalutamide was well tolerated, with a manageable toxicity profile and a modest objective response rate. A considerable difference in serum levels of PSA before and after treatment was observed. A significant …